APM
Aptorum Group Limited
NASDAQ · Healthcare · Biotechnology · GB
$8.26
−14.84%Price chart
Jul 31Aug 5Aug 10Aug 13Aug 18Aug 21Aug 26Aug 31
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.0x
Market Cap
$67.27M
MomentumView details →
1D Return
−14.84%
YTD Return
−35.28%
RSI (14)
35.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−9.0x
Market Cap
$67.27M
RSI (14)
35.0
MomentumView details →
1D Return
−14.84%
YTD Return
−35.28%
SummaryUpdated Jun 1, 2026
Aptorum Group Limited (NASDAQ:APM) is a London-headquartered biopharmaceutical company that was incorporated in 2010 and went public in December 2018. The company focuses on discovering, developing, and commercializing therapeutic products primarily for infectious diseases and cancer treatment. As a clinical-stage biotechnology firm, Aptorum operates with a diverse pipeline of drug candidates spanning multiple therapeutic areas including oncology, infectious diseases, neurology, and metabolic disorders, while also maintaining a small medical clinic operation.
Similar companies
Latest newsMore news →
Aptorum Group provided an update on its merger with DiamiR Biosciences, resulting in the post-merger company Niki BioSolutions, Inc. trading on Nasdaq under ticker NIKI.50d agoAptorum Group announced a collaboration between DiamiR Biosciences and AlzLabs Precision Diagnostics to generate biomarker data for Alzheimer's disease.74d agoAptorum Group shareholders approved a merger with DiamiR Biosciences.86d ago